In addition, Buddlejasaponin IV (BS-IV) acts as an anti-metastatic agent by reducing FAK and Akt phosphorylation levels, which inhibits the lung metastases of colon cancer cells [137]. Here, AKT1 is linked to colonic neoplasm.